RU2007114908A - Применение агонистов аденозиновых рецепторов a2a - Google Patents
Применение агонистов аденозиновых рецепторов a2a Download PDFInfo
- Publication number
- RU2007114908A RU2007114908A RU2007114908/142007114908/14A RU2007114908A RU2007114908A RU 2007114908 A RU2007114908 A RU 2007114908A RU 2007114908 A RU2007114908 A RU 2007114908A RU 2007114908 A RU2007114908 A RU 2007114908A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- single dose
- administered
- person
- administering
- Prior art date
Links
- 239000002465 adenosine A2a receptor agonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 23
- 238000000034 method Methods 0.000 claims abstract 19
- 230000017531 blood circulation Effects 0.000 claims abstract 4
- 230000024883 vasodilation Effects 0.000 claims abstract 4
- 238000003384 imaging method Methods 0.000 claims abstract 2
- 210000004165 myocardium Anatomy 0.000 claims abstract 2
- 230000010412 perfusion Effects 0.000 claims abstract 2
- 230000002093 peripheral effect Effects 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract 2
- 230000002107 myocardial effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Abstract
1. Способ создания коронарной вазодилатации с незначительной периферической вазодилатацией, включающий введение человеку однократной дозы фармацевтической композиции, содержащей регаденосон и по меньшей мере один фармацевтический наполнитель в количестве, которое является достаточным для увеличения средней пиковой скорости коронарного кровотока по меньшей мере на приблизительно 16,5 см/с.2. Способ по п.1, в котором указанная однократная доза фармацевтической композиции вводится в/в болюсно.3. Способ по п.1, в котором указанная однократная доза фармацевтической композиции вводится за время от приблизительно 10 до приблизительно 20 с.4. Способ по п.1, в котором количество однократной дозы вводимой фармацевтической композиции является достаточным для повышения средней пиковой скорости коронарного кровотока приблизительно на 16,5-77,0 см/с.5. Способ по п.1, в котором однократная доза фармацевтической композиции содержит от приблизительно 10 до приблизительно 500 мкг регаденосона.6. Способ по п.1, в котором однократная доза фармацевтической композиции содержит регаденосон в количестве в пределах от приблизительно 0,05 до приблизительно 60 мкг/кг.7. Способ по п.1, в котором перфузионная визуализация миокарда человека выполняется после введения человеку однократной дозы фармацевтической композиции.8. Способ по п.7, дополнительно включающий введение по меньшей мере одного радионуклида человеку во время, выбранное из группы, состоящей из введения до получения человеком дозы фармацевтической композиции, одновременно с введением дозы фармацевтической композиции или после введения человеку дозы фармацевтической композиции.9.
Claims (11)
1. Способ создания коронарной вазодилатации с незначительной периферической вазодилатацией, включающий введение человеку однократной дозы фармацевтической композиции, содержащей регаденосон и по меньшей мере один фармацевтический наполнитель в количестве, которое является достаточным для увеличения средней пиковой скорости коронарного кровотока по меньшей мере на приблизительно 16,5 см/с.
2. Способ по п.1, в котором указанная однократная доза фармацевтической композиции вводится в/в болюсно.
3. Способ по п.1, в котором указанная однократная доза фармацевтической композиции вводится за время от приблизительно 10 до приблизительно 20 с.
4. Способ по п.1, в котором количество однократной дозы вводимой фармацевтической композиции является достаточным для повышения средней пиковой скорости коронарного кровотока приблизительно на 16,5-77,0 см/с.
5. Способ по п.1, в котором однократная доза фармацевтической композиции содержит от приблизительно 10 до приблизительно 500 мкг регаденосона.
6. Способ по п.1, в котором однократная доза фармацевтической композиции содержит регаденосон в количестве в пределах от приблизительно 0,05 до приблизительно 60 мкг/кг.
7. Способ по п.1, в котором перфузионная визуализация миокарда человека выполняется после введения человеку однократной дозы фармацевтической композиции.
8. Способ по п.7, дополнительно включающий введение по меньшей мере одного радионуклида человеку во время, выбранное из группы, состоящей из введения до получения человеком дозы фармацевтической композиции, одновременно с введением дозы фармацевтической композиции или после введения человеку дозы фармацевтической композиции.
9. Способ по п.7, в котором радионуклид и однократная доза фармацевтической композиции вводятся человеку отдельно.
10. Способ по п.7, в котором радионуклид и однократная доза фармацевтической композиции вводятся человеку одновременно.
11. Способ по п.7, в котором исследование миокарда начинается не ранее, чем через приблизительно 1 мин после введения человеку однократной дозы фармацевтической композиции.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62057704P | 2004-10-20 | 2004-10-20 | |
US60/620,577 | 2004-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007114908A true RU2007114908A (ru) | 2008-10-27 |
Family
ID=35953984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007114908/142007114908/14A RU2007114908A (ru) | 2004-10-20 | 2005-10-19 | Применение агонистов аденозиновых рецепторов a2a |
Country Status (13)
Country | Link |
---|---|
US (3) | US7655636B2 (ru) |
EP (1) | EP1802317A2 (ru) |
JP (1) | JP2008517063A (ru) |
KR (1) | KR20070083714A (ru) |
CN (1) | CN101076343A (ru) |
AU (1) | AU2005295437B2 (ru) |
CA (1) | CA2583185A1 (ru) |
IL (1) | IL182645A0 (ru) |
MX (1) | MX2007004749A (ru) |
NO (1) | NO20072540L (ru) |
RU (1) | RU2007114908A (ru) |
WO (1) | WO2006044856A2 (ru) |
ZA (1) | ZA200703229B (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
AU2001238665A1 (en) * | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
CN1671399A (zh) * | 2002-07-29 | 2005-09-21 | Cv医药有限公司 | 利用a2a受体激动剂的心肌灌注显像 |
CA2583185A1 (en) | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
EP2581381A3 (en) * | 2006-02-03 | 2013-10-30 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
JP2009541354A (ja) * | 2006-06-22 | 2009-11-26 | シーブイ・セラピューティクス・インコーポレイテッド | 虚血の治療におけるa2aアデノシン受容体アゴニストの使用 |
WO2008028140A1 (en) * | 2006-09-01 | 2008-03-06 | Cv Therapeutics, Inc. | Methods and compositions for increasing patient tolerability during myocardial imaging methods |
US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
CA2663361A1 (en) * | 2006-09-29 | 2008-04-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
WO2008086096A2 (en) * | 2007-01-03 | 2008-07-17 | Cv Therapeutics, Inc. | Myocardial perfusion imaging |
JP2012504147A (ja) * | 2008-09-29 | 2012-02-16 | ギリアード サイエンシーズ, インコーポレイテッド | 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびA−2−α受容体作動薬の組み合わせ |
WO2014083580A2 (en) * | 2012-11-30 | 2014-06-05 | Leiutis Pharmaceuticals Pvt. Ltd. | Pharmaceutical compositions of regadenoson |
WO2017059302A1 (en) * | 2015-09-30 | 2017-04-06 | Cedars-Sinai Medical Center | Robust myocardial blood oxygen level dependent magnetic resonance imaging with long-acting coronary vasodilators |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK135130B (da) | 1970-12-28 | 1977-03-07 | Takeda Chemical Industries Ltd | Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf. |
BE787064A (fr) | 1971-08-03 | 1973-02-01 | Philips Nv | Dispositif magnetique comportant des domaines |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4089959A (en) | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
US4120947A (en) | 1976-03-31 | 1978-10-17 | Cooper Laboratories, Inc. | Xanthine compounds and method of treating bronchospastic and allergic diseases |
US4069959A (en) * | 1976-10-27 | 1978-01-24 | Butler Automatic, Inc. | Web guide apparatus |
SE7810946L (sv) | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4593095A (en) | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4696932A (en) | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
JPS6299395A (ja) | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | 2−アルキニルアデノシンおよび抗高血圧剤 |
US4968697A (en) | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5070877A (en) | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
DE3831430A1 (de) * | 1988-09-15 | 1990-03-22 | Bayer Ag | Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
KR0137786B1 (ko) | 1988-11-15 | 1998-05-15 | 하마구찌 미찌오 | 심장 또는 뇌의 허혈성 질환의 치료, 예방제 |
IT1229195B (it) | 1989-03-10 | 1991-07-25 | Poli Ind Chimica Spa | Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche. |
DE69022176T2 (de) | 1989-06-20 | 1996-02-15 | Toa Eiyo Ltd., Tokio/Tokyo | Zwischenverbindung für 2-alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2-alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat. |
US5032252A (en) | 1990-04-27 | 1991-07-16 | Mobil Oil Corporation | Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator |
DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
US5189027A (en) | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
FR2671356B1 (fr) | 1991-01-09 | 1993-04-30 | Inst Nat Sante Rech Med | Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu. |
JP2740362B2 (ja) | 1991-02-12 | 1998-04-15 | ヤマサ醤油株式会社 | 安定な固体状2‐オクチニルアデノシンおよびその製造法 |
JP3053908B2 (ja) | 1991-06-28 | 2000-06-19 | ヤマサ醤油株式会社 | 2‐アルキニルアデノシン誘導体 |
US5516894A (en) | 1992-03-11 | 1996-05-14 | The General Hospital Corporation | A2b -adenosine receptors |
IT1254915B (it) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
GB9210839D0 (en) | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
JPH08500967A (ja) | 1992-06-12 | 1996-02-06 | ガーヴァン インスティチュート オブ メディカル リサーチ | ヒトA1,A2aおよびA2bアデノシン受容体をエンコードするDNA配列 |
US5705491A (en) | 1992-10-27 | 1998-01-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Adenosine deaminase inhibitor |
CA2112031A1 (en) | 1992-12-24 | 1994-06-25 | Fumio Suzuki | Xanthine derivatives |
WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
DE69526822T2 (de) | 1994-02-23 | 2003-01-23 | Kyowa Hakko Kogyo Kk | Xanthin-derivate |
US5704491A (en) | 1995-07-21 | 1998-01-06 | Cummins-Allison Corp. | Method and apparatus for discriminating and counting documents |
US5646156A (en) | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
US6514949B1 (en) * | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US5854081A (en) | 1996-06-20 | 1998-12-29 | The University Of Patent Foundation | Stable expression of human A2B adenosine receptors, and assays employing the same |
US5780481A (en) | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
US5776960A (en) | 1996-10-16 | 1998-07-07 | Buckman Laboratories International, Inc. | Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same |
US5770716A (en) | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
EP0983768A1 (en) | 1997-05-23 | 2000-03-08 | Nippon Shinyaku Co., Ltd. | Medicinal composition for prevention or treatment of hepatopathy |
AU740770B2 (en) | 1997-06-18 | 2001-11-15 | Aderis Pharmaceuticals, Inc. | Compositions and methods for preventing restenosis following revascularization procedures |
US6026317A (en) | 1998-02-06 | 2000-02-15 | Baylor College Of Medicine | Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists |
US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
AU4675699A (en) | 1998-06-08 | 1999-12-30 | Epigenesis Pharmaceuticals, Inc. | Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
US6214807B1 (en) | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
JP3914434B2 (ja) | 1999-08-31 | 2007-05-16 | ヴァンダービルト ユニヴァーシティ | A2bアデノシン受容体の選択的アンタゴニスト |
US6368573B1 (en) | 1999-11-15 | 2002-04-09 | King Pharmaceuticals Research And Development, Inc. | Diagnostic uses of 2-substituted adenosine carboxamides |
US6294522B1 (en) | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
US6605597B1 (en) | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
US6677336B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
AU2001238665A1 (en) | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
US6387913B1 (en) | 2000-12-07 | 2002-05-14 | S. Jamal Mustafa | Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists |
US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
US6995148B2 (en) | 2001-04-05 | 2006-02-07 | University Of Pittsburgh | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy |
US6599283B1 (en) | 2001-05-04 | 2003-07-29 | Cv Therapeutics, Inc. | Method of preventing reperfusion injury |
ES2340664T3 (es) | 2001-05-14 | 2010-06-08 | Novartis Ag | Derivados de sulfonamidas. |
US20030235555A1 (en) | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US7125993B2 (en) | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
EP1444233B1 (en) | 2001-11-09 | 2011-08-17 | Gilead Palo Alto, Inc. | A2b adenosine receptor antagonists |
US6916804B2 (en) | 2001-12-20 | 2005-07-12 | Osi Pharmaceuticals, Inc. | Pyrimidine A2b selective antagonist compounds, their synthesis and use |
US20050020915A1 (en) | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
CN1671399A (zh) | 2002-07-29 | 2005-09-21 | Cv医药有限公司 | 利用a2a受体激动剂的心肌灌注显像 |
CA2691611A1 (en) * | 2004-01-27 | 2005-09-09 | Gilead Palo Alto, Inc. | Myocardial perfusion imaging using adenosine receptor agonists |
WO2006044610A1 (en) | 2004-10-15 | 2006-04-27 | Cv Therapeutics, Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
CA2583185A1 (en) | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
AU2006204716A1 (en) | 2005-01-12 | 2006-07-20 | King Pharmaceuticals Reserch & Development, Inc. | Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm |
EP2581381A3 (en) | 2006-02-03 | 2013-10-30 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
JP2009541354A (ja) | 2006-06-22 | 2009-11-26 | シーブイ・セラピューティクス・インコーポレイテッド | 虚血の治療におけるa2aアデノシン受容体アゴニストの使用 |
WO2008028140A1 (en) | 2006-09-01 | 2008-03-06 | Cv Therapeutics, Inc. | Methods and compositions for increasing patient tolerability during myocardial imaging methods |
US20090081120A1 (en) | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
CA2663361A1 (en) | 2006-09-29 | 2008-04-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
WO2008086096A2 (en) | 2007-01-03 | 2008-07-17 | Cv Therapeutics, Inc. | Myocardial perfusion imaging |
JP2012504147A (ja) | 2008-09-29 | 2012-02-16 | ギリアード サイエンシーズ, インコーポレイテッド | 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびA−2−α受容体作動薬の組み合わせ |
-
2005
- 2005-10-19 CA CA002583185A patent/CA2583185A1/en not_active Abandoned
- 2005-10-19 JP JP2007537961A patent/JP2008517063A/ja not_active Withdrawn
- 2005-10-19 AU AU2005295437A patent/AU2005295437B2/en not_active Ceased
- 2005-10-19 KR KR1020077008782A patent/KR20070083714A/ko not_active Application Discontinuation
- 2005-10-19 US US11/253,322 patent/US7655636B2/en not_active Expired - Fee Related
- 2005-10-19 CN CNA2005800356405A patent/CN101076343A/zh active Pending
- 2005-10-19 WO PCT/US2005/037368 patent/WO2006044856A2/en active Application Filing
- 2005-10-19 EP EP05815368A patent/EP1802317A2/en not_active Withdrawn
- 2005-10-19 MX MX2007004749A patent/MX2007004749A/es not_active Application Discontinuation
- 2005-10-19 RU RU2007114908/142007114908/14A patent/RU2007114908A/ru not_active Application Discontinuation
-
2007
- 2007-04-18 IL IL182645A patent/IL182645A0/en unknown
- 2007-04-19 ZA ZA200703229A patent/ZA200703229B/xx unknown
- 2007-05-18 NO NO20072540A patent/NO20072540L/no not_active Application Discontinuation
-
2009
- 2009-12-14 US US12/637,583 patent/US8106029B2/en active Active
-
2011
- 2011-12-21 US US13/333,789 patent/US20120189538A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7655636B2 (en) | 2010-02-02 |
WO2006044856A3 (en) | 2006-07-06 |
US20060084625A1 (en) | 2006-04-20 |
JP2008517063A (ja) | 2008-05-22 |
ZA200703229B (en) | 2009-07-29 |
EP1802317A2 (en) | 2007-07-04 |
US8106029B2 (en) | 2012-01-31 |
AU2005295437A1 (en) | 2006-04-27 |
CA2583185A1 (en) | 2006-04-27 |
NO20072540L (no) | 2007-05-18 |
US20120189538A1 (en) | 2012-07-26 |
MX2007004749A (es) | 2007-06-18 |
WO2006044856A2 (en) | 2006-04-27 |
AU2005295437B2 (en) | 2011-05-19 |
CN101076343A (zh) | 2007-11-21 |
KR20070083714A (ko) | 2007-08-24 |
IL182645A0 (en) | 2007-07-24 |
US20100158797A1 (en) | 2010-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007114908A (ru) | Применение агонистов аденозиновых рецепторов a2a | |
Theiss et al. | Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis | |
RU2009106862A (ru) | Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда | |
HRP20200096T1 (hr) | Oralne formulacije analoga citidina i postupci za njihovu upotrebu | |
JP2010502649A5 (ru) | ||
EP2392326B1 (en) | Silibinin component for the treatment of hepatitis | |
CA2492855A1 (en) | Myocardial perfusion imaging using a2a receptor agonists | |
HASHIMOTO et al. | THE PHARMACOLOGICAL FEATURES OF THE CORONARY, RENAL. MESENTERIC AND FEMORAL ARTERIES | |
JP2005538190A5 (ru) | ||
AU2014248116A1 (en) | Hepatitis C viral infection treatment using a combination of compounds | |
CN103432133A (zh) | 核受体结合剂的用途 | |
BR0308137A (pt) | Formulações de droga de liberação constante contendo um peptìdeo veìculo | |
CA2466228A1 (en) | Method for treating diseases with omega interferon | |
Johnson‐Ansah et al. | Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia | |
CN104173312A (zh) | 一种含有非洛地平和美托洛尔盐的缓释片及其制备方法 | |
CA2554169A1 (en) | Myocardial perfusion imaging using adenosine receptor agonists | |
CN106138019A (zh) | Gpr35受体激动剂及其应用 | |
JP2004506684A (ja) | 肝細胞への薬物送達及びフラビウイルス感染症の治療の方法 | |
HRP20010496A2 (en) | Modulation of immune response by ribavirin | |
Sadeque et al. | Systemic ketoconazole in the treatment of tinea versicolor. | |
EP2959901A1 (en) | Pharmaceutical combinations of sofosbuvir and ribavirin | |
TW200501967A (en) | Nemorubicin for use in the preparation of a medicament for liver disease | |
EP2959888A1 (en) | A novel pharmaceutical composition of sofosbuvir and ribavirin | |
WO2023114871A1 (en) | Use of combination therapy for treating cancer | |
CN104274453A (zh) | 一种抗结核药物的二联复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20090111 |
|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20090111 |